Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. Eiger's pipeline includes preclinical new chemical entities from internal discovery efforts, as well as repurposed clinical and approved drugs shown to possess novel antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses.
Drais Pharmaceuticals is a pharmaceutical company headquartered in Bridgewater, New Jersey, dedicated to the development of novel therapeutic treatments that address unmet medical needs and provide significant benefits over currently available therapies.
CVRx has developed an implantable device that is designed to treat high blood pressure and heart failure in patients with drug resistant hypertension. The Barostim neo system triggers the baroreflex, which is the body’s master blood-flow regulation system. The system is CE Marked and approved for use by hypertension patients in Europe.
AGTC develops therapeutics for patients with unmet medical needs utilizing the non-pathogenic adeno-associated virus to deliver therapeutic genes. AGTC secured rights to a portfolio of strategically vital intellectual property in the application of Adeno-Associated Virus to gene therapy. AGTC has signed licenses to over 40 U.S. and foreign patents, and has five products in active development
Doximity is a free communication platform that helps connect medical professionals in 87 specialties to enable faster, smarter medical care. With Doximity, physicians can use their iPhone, iPad, Android device or computer to quickly connect with any U.S. physician to collaborate on patient treatment or identify appropriate experts for patient referrals.
KAI is a clinical-stage, biopharmaceutical company whose lead peptide product candidate, KAI-4169, is in development for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). CKD-MBD is characterized by an elevation of parathyroid hormone also referred to as secondary hyperparathyroidism. KAI was acquired by Amgen in 2012.
Restoration Robotics is revolutionizing the field of hair transplantation by developing and commercializing ARTAS, a state-of-the-art image-guided system that improves the follicular unit extraction process. The office-based device is capable of rapidly harvesting and implanting individual hairs with minimal invasion, automating the tedious manual surgical technique now being performed by hair transplant surgeons.
Integrated Diagnostics develops large-scale, blood-based molecular diagnostics that leverage advances in proteomics and genomics to detect disease at its earliest stage. It leverages emerging technologies to develop diagnostic products used by physicians and patients to manage complex and serious diseases like cancer, diabetes and Alzheimer's. The company’s products work through blood tests that can monitor tens to hundreds of disease markers simultaneously. Integrated Diagnostics is headquartered in Seattle, Washington.
BioMimetic Therapeutics develops and commercializes clinically proven products to promote the healing of musculoskeletal injuries and diseases, including therapies for orthopedic and sports medicine applications. BioMimetic has become a leader in regenerative medicine by providing new treatment options for the repair of bone, cartilage, tendons and ligaments.
Cebix is a biopharmaceutical company focused on the development of chronic replacement therapy based on human proinsulin C-peptide for the treatment of diabetic complications, initially peripheral neuropathy in patients with type 1 diabetes.